Info Edge(India) Ltd. — Capital/Financing Update 2020

May 21, 2020

Date: May 21, 2020

1. The Manager- Listing National Stock Exchange of India Limited (Scrip Code: NAUKRI)

2. The Manager- Listing BSE Limited (Scrip Code: 532777)

Dear Sir/Madam ,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

The Company would like to inform you that IE Venture Fund I has entered into an agreement to invest about Rs.3.70 Crore in Intellihealth Solutions Private Limited. The details of the transaction are given as under:

Sl. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Intellihealth Solutions Private Limited (“Truemeds”) No. 306, A-WING, 3rd Floor,Pranik Chamber Owners Co.op Prem Society Ltd, Saki Vihar Road, Sakinaka Mumbai -400072 Turnover (As on 31.03.2020):Rs. 1 Crore (Unaudited Figure)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Truemeds is not a Related Party as on the date of making this Investment. Promoters of the Company have no interest in the said investment. The transaction is done at Arm’s Length basis.
3.	Industry to which the entity being acquired belongs	Truemeds is a Tele-health platform focused on selling top company Traded Generics/substitute medicines to consumers. Its telemedicine platform of doctors advises consumers about substitute medicines (offered by top pharma companies but at much cheaper costs) which could significantly reduce cost of their medical bills.
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity.	The said investment would help IE Venture Fund I to support and grow Truemeds business in India.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.

	6.	Indicative timeperiod for completion of acquisition	Indicative timeperiod for completion of acquisition	Immediate
	7.	Nature of Consideration-	whether cash	Cash Consideration
		consideration or share swapand	details of the same.
	8.	Cost of acquisition or the price	at which the shares	About Rs. 3.70 Crore
		are acquired.
	9.	Percentage of shareholding/control acquired and/ or		The IE Venture Fund I has agreed to acquire
		number of shares acquired.		24,980 -0.01% Series Seed Compulsorily
				Convertible Preference Shares having Face
				value of Rs.10/- each at a premium of
				Rs.1,468.79/-. The aggregate shareholding of IE
				Venture Fund I, post this investment, in
				Truemeds would be 17.80% on a fully
				converted & diluted basis.
	10.	Brief background about the entity acquired in terms		Truemeds which was incorporated on February
		of products/line of business	acquired, date of	1, 2019 is a Tele-health platform focused on
		incorporation, history of last	3 years turnover,	selling top company Traded Generics/substitute
		country in which the acquired entity has presence		medicines to consumers. Its telemedicine
		and any other significant information (in brief).		platform of doctors advises consumers about
				substitute medicines (offered by top pharma
				companies but at much cheaper costs) which
				could significantly reduce cost of their medical
				bills.
				Last threeyears turnover:
				2019-2020 2018-19 2017-2018
				Rs. 1 Crore
				(Unaudited NA NA
				figure)
This is for your information and records.
Thanking You.
Yours faithfully,
ForInfo		Edge (India) Ltd.
MM Jain
SVP- Secretarial & Company Secretary